LSALT Drug Development program to mitigate COVID-19 related Organ (Lung and Kidney) damage and inflammation
$4,000,000.00
Grant Value
2023-24
Fiscal Year
Description
The project targets the prevention of acute organ inflammation injury in the lungs and kidneys of patients who have moderate to severe COVID-19 and other diseases. LSALT peptide is a novel drug candidate and selective dipeptidase-1 inhibitor which blocks injury in the lungs and kidneys by reducing leukocyte recruitment and inflammation in these organs. This project focuses on completing the clinical and commercial drug development tasks needed to obtain regulatory approval for LSALT peptide. A successful project will advance the LSALT peptide as a new therapeutic that will reduce organ inflammation complications in high risk patients, increase survival rates and provide resiliency in the Canadian healthcare system for future pandemics.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Grant Details
Recipient
Arch Biopartners Inc.
Location
Toronto, ON M4T 2M5
Agreement Details
Number: 1003639
Reference: 172-2022-2023-Q4-1003639
Timeline
Start: Nov. 1, 2022
End: March 31, 2024
Program
Industrial Research Assistance Program Contributions to Firms
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or …
Sector
Manufacturing (334512)
Your Contribution
Calculate how much you personally contributed to this grant through your taxes.
Calculate My Share